TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Neuren Pharmaceuticals Limited ( (AU:NEU) ) just unveiled an announcement.
Neuren Pharmaceuticals announced the inclusion of SYNGAP1-related disorder (SRD) in its NNZ-2591 drug development pipeline after positive pre-clinical results. This addition addresses a significant unmet need as there are currently no approved treatments for SRD, a condition caused by a genetic variant leading to neurological issues. The company’s NNZ-2591 has shown promise in reversing neuronal dysfunction in SRD models, and Neuren is preparing for a Phase 3 trial in Phelan-McDermid syndrome, highlighting its commitment to tackling rare neurodevelopmental disorders.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$29.90 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals is focused on developing new drug therapies for serious neurological disorders that emerge in early childhood, many of which have no or limited approved treatment options. The company has been granted ‘orphan drug’ designation in the United States for its programs, which encourages the development of therapies for rare and serious diseases. Neuren’s product DAYBUE™ is approved for Rett syndrome, and NNZ-2591 is under development for multiple neurodevelopmental disorders.
Average Trading Volume: 530,003
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$2.13B
For an in-depth examination of NEU stock, go to TipRanks’ Overview page.